Table 3.
Post-hoc p-values* |
Post-hoc p-values* |
Global three way ANOVA |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cytokines | ANOVA P-value pCR in both arms | ANOVA pCR Chemotherapy-only arm | 0 W | 12 W | 25 W | 31 W | ANOVA pCR Combination (+Bev) arm | 0 W | 12 W | 25 W | 31 W | Raw p-valuea | FDR-adjusted p-valueb |
IL1B | 0.044 | 0.503 | 0.679 | ||||||||||
IL1-RA | 0.077 | 0.539 | 0.693 | ||||||||||
IL2 | 0.109 | 0.062 | 0.152 | ||||||||||
IL4 | 0.003 | 0.402 | 0.021 | 0.3 | 0.028 | 0.053 | 0.27 | 0.025 | 0.075 | ||||
IL5 | 0.001 | 0.205 | 0.012 | 0.6 | 0.151 | 0.055 | 0.14 | 0.013 | 0.044 | ||||
IL6 | 0.137 | 0.716 | 0.773 | ||||||||||
IL7 | 0.072 | 0.079 | 0.178 | ||||||||||
IL8 | 0.136 | 0.487 | 0.679 | ||||||||||
IL9 | 0.13 | 0.343 | 0.579 | ||||||||||
IL10 | 0.039 | 0.405 | 0.31 | 0.006 | 0.023 | ||||||||
IL12 (P70) | <0.001 | 0.202 | 0.45 | <0.001 | <0.001 | ||||||||
IL13 | 0.059 | 0.255 | 0.492 | ||||||||||
IL15 | 0.569 | 0.955 | 0.955 | ||||||||||
IL17-A | 0.031 | 0.539 | 0.022 | 0.7 | 0.067 | 0.19 | 0.12 | 0.037 | 0.1 | ||||
Eotaxin (CCL11) | 0.034 | 0.131 | 0.272 | ||||||||||
FGF-basic | 0.093 | 0.485 | 0.679 | ||||||||||
G-CSF (CSF3) | 0.002 | 0.419 | 0.12 | 0.004 | 0.022 | ||||||||
GM-CSF (CSF2) | 0.233 | 0.649 | 0.762 | ||||||||||
IFN-gamma | <0.001 | 0.154 | 0.003 | 0.6 | 0.038 | 0.086 | 0.08 | 0.006 | 0.023 | ||||
IP10 (CXCL10) | 0.006 | 0.014 | 0.1 | 0.037 | 0.33 | 0.6 | 0.725 | <0.001 | <0.001 | ||||
MCP-1 (CCL2) | 0.366 | 0.627 | 0.762 | ||||||||||
MIP-1a (CCL3) | 0.011 | 0.317 | 0.571 | ||||||||||
MIP-Ib (CCL4) | 0.127 | 0.706 | 0.773 | ||||||||||
PDGF-bb | 0.529 | <0.001 | <0.001 | ||||||||||
RANTES (CCL5) | 0.565 | 0.931 | 0.955 | ||||||||||
TNF-alpha | 0.008 | 0.289 | 0.006 | 0.6 | 0.027 | 0.046 | 0.22 | 0.447 | 0.679 | ||||
VEGF-A | 0.006 | 0.358 | 0.7 | 0.158 | 0.86 | 0.033 | 0.034 | 0.9 | 0.015 | 0.103 | 0.21 | 0.003 | 0.02 |
Post-hoc t-tests for pairwise comparisons with multiple testing adjusted by Bonferroni; performed only if ANOVA P<0.05 (and if global three-way ANOVA FDR-adjusted p<0.1, or if TNF-alpha). W = week.
Global F-test in three-way ANOVA with treatment (2 levels), timepoint (4 levels) and treatment response (2 levels) as fixed factors.
FDR-adjustment with the method of Benjamini-Hochberg.